MINNEAPOLIS, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company, announced today it received an extension of 180 calendar days from the Nasdaq Stock Market LLC ("Nasdaq") to regain compliance with the Nasdaq’s minimum $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market (the “Bid Price Requirement”), following the expiration of the initial 180 calendar days period to regain compliance on November 28, 2022.
As a result of the extension, the Company now has until May 29, 2023 to regain compliance with the Bid Price Requirement. If at any time before May 29, 2023, the bid price of the Company’s common shares closes at or above US$1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written notification to the Company that it has achieved compliance with the Bid Price Requirement.
This current notification from Nasdaq has no immediate effect on the listing or trading of the Company’s shares, which will continue to trade on the Nasdaq Capital Market under the symbol “NUWE”.
Recent NUWE News
- Nuwellis to Present at the Third Annual ROTH Healthcare Opportunities Conference • GlobeNewswire Inc. • 09/25/2024 08:15:00 PM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 08/30/2024 08:11:06 PM
- New Study Published in Current Problems in Cardiology Highlights Statistically Significant Reduction in Heart Failure Readmissions at 60 days when using the Aquadex Ultrafiltration Therapy • GlobeNewswire Inc. • 08/27/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/26/2024 08:45:39 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/24/2024 01:31:56 AM
- Nuwellis Announces Pricing of $916,000 Registered Direct Offering Priced At-The-Market Under Nasdaq Rules • GlobeNewswire Inc. • 08/23/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 09:10:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 05:00:16 PM
- Nuwellis, Inc. Announces Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 08/13/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 01:15:42 PM
- Nasdaq Panel Grants Nuwellis Continued Listing on the Nasdaq Stock Market, Subject to Conditions • GlobeNewswire Inc. • 08/08/2024 01:00:00 PM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 08/02/2024 08:12:11 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 08/02/2024 07:05:58 PM
- Nuwellis Announces First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical’s QUELIMMUNE™ Therapy at Cincinnati Children’s • GlobeNewswire Inc. • 07/26/2024 01:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/25/2024 01:25:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/25/2024 12:31:38 PM
- Nuwellis Announces Pricing of $2.0 Million Offering Priced At-The-Market Under Nasdaq Rules • GlobeNewswire Inc. • 07/24/2024 12:02:35 PM
- Nuwellis, Inc. To Report Second Quarter 2024 Financial Results on August 13, 2024 • GlobeNewswire Inc. • 07/23/2024 08:10:00 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 07/17/2024 08:01:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/17/2024 01:12:51 PM
- Nuwellis Marks First Commercial Sale of QUELIMMUNE™ Therapy to Cincinnati Children’s • GlobeNewswire Inc. • 07/17/2024 01:00:00 PM
- SeaStar Medical Ships First QUELIMMUNE Product Order to U.S. Distribution Partner • GlobeNewswire Inc. • 07/12/2024 12:30:00 PM
- New Evidence on Aquadex Ultrafiltration Therapy to be Presented at HFSA 2024 Conference • GlobeNewswire Inc. • 07/09/2024 01:00:00 PM
- Nuwellis Announces Reverse Stock Split • GlobeNewswire Inc. • 06/26/2024 12:45:00 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM